ライフサイエンスコーパス: primary lung cancer

1 umab may be a therapeutic drug candidate for primary lung cancer.

2 tatus of brain metastases, and the status of primary lung cancer.

3 nts treated with RFA for lung metastases and primary lung cancers.

4 d are lost together in cancer cell lines and primary lung cancers.

5 cancers which we have confirmed in 40 other primary lung cancers.

6 that lack of gene expression also occurs in primary lung cancers.

7 and human mutT, were abundantly expressed in primary lung cancers (10 of 18, 15 of 18, and 6 of 12 tu

8 All instances of first diagnosis of primary lung cancer after a negative screening result 7-

9 nt ages at diagnoses: age 40 to 49 years for primary lung cancer; age 50 to 59 years for primary mela

10 omen; age range, 49-82 years) with untreated primary lung cancer and 17 women with untreated primary

11 The subjects were 89 cases of primary lung cancer and 173 controls, all males, matched

12 rs to be promising as a prognostic factor in primary lung cancer and as a noninvasive tumor marker in

13 on of the Fus1 protein was observed in human primary lung cancer and cancer cell lines.

14 culosis, to community acquired pneumonia and primary lung cancer and healthy controls, before and aft

15 Fifty-six chest radiographs of 34 primary lung cancers and 22 benign nodules were digitize

16 fty-three chest radiographs that depicted 31 primary lung cancers and 22 benign nodules were used.

17 Low or undetectable NEP is present in many primary lung cancers and cell lines.

18 ated with overexpression of these targets in primary lung cancers and coincided with DNA methylation,

19 he PGP9.5 transcript was highly expressed in primary lung cancers and lung cancer cell lines but was

20 ve shown that PGP9.5 was highly expressed in primary lung cancers and lung cancer cell lines.

21 were sequence analyzed from two independent primary lung cancers and two normal human bronchial/trac

22 as PC (39 proven, 37 highly probable), 7 as primary lung cancer, and 2 as activated tuberculosis; 4

23 cohort design, we evaluated 587 patients of primary lung cancer at two tertiary care facilities.

24 s, was significantly increased (5.7-fold) in primary lung cancers but not adjacent tissues.

25 ARgamma protein was also expressed in 50% of primary lung cancers by immunohistochemistry.

26 studied in paraffin sections from untreated primary lung cancers by immunohistochemistry.

27 LC), along with a surgical resection for the primary lung cancer, can be curative.

28 Primary lung cancer cases (n = 2,101) were recruited fro

29 ONYX-015 lysed primary lung cancer cells in six of seven (86 %) primary

30 Primary lung cancer cells isolated from patient lung tum

31 essive therapy, the most likely culprits are primary lung cancer, chronic infectious or inactive gran

32 gs of 13 patients due to undergo surgery for primary lung cancer (five of 13) or spontaneous pneumoth

33 374 uveal metastatic tumors originating from primary lung cancer in 229 eyes of 194 patients.

34 f uveal metastasis preceded the diagnosis of primary lung cancer in 44% of patients.

35 during the development of chemically induced primary lung cancer in mice.

36 A 5% rate of stage I primary lung cancer in patients selected for lung volume

37 te reliably between pulmonary metastases and primary lung cancer in PC patients.

38 FDG PET led to a biopsy-proved diagnosis of primary lung cancer in two patients.

39 ung cancer (SPLC) among survivors of initial primary lung cancer (IPLC) and evaluated the clinical ut

40 nd lesions of different origin, for example, primary lung cancer, is a common clinical question.

41 issue, RSK1 was reduced in metastatic versus primary lung cancer lesions.

42 tiple lung cancers to differentiate multiple primary lung cancers (MPLCs) from pulmonary metastases.

43 y lesions, including metastases (n = 38) and primary lung cancers (n = 44), underwent RFA.

44 he derivation of these tumors, either as new primary lung cancers or as metastatic head and neck canc

45 Three patients had synchronous primary lung cancers or multifocal disease.

46 /- 3.9 for PC metastases and 5.6 +/- 1.6 for primary lung cancer (P = 0.408).

47 metastases recurred less often than treated primary lung cancers (P = 0.03).

48 Primary lung cancer remains the leading cause of cancer-

49 imated the 10-year risk of developing second primary lung cancer (SPLC) among survivors of initial pr

50 ng cancer) and expression of DeltaDNMT3B4 in primary lung cancer, suggesting a role of DeltaDNMT3B in

51 cancer, breast cancer, and mesothelioma) and primary lung cancer tissue samples.

52 d in the lung and is down-regulated in human primary lung cancer tissues and cell lines.

53 etected methylation of APC in 95 of 99 (96%) primary lung cancer tissues.

54 We evaluated primary lung cancers, tumor cell lines, and preneoplasti

55 Primary lung cancer tumors in 21 patients were measured

56 emission tomography (PET) scans obtained in primary lung cancer tumors.

57 adenocarcinomas and other non-neuroendocrine primary lung cancer types in the right upper lobe.

58 The likelihood of a primary lung cancer versus a metastasis depends on the h

59 four analyzable patients who had surgery for primary lung cancer were included.

60 Between 2002 and 2005, 2,100 patients with primary lung cancer were recruited from 13 hospitals wit

61 Eighty-three primary lung cancers were found during an annual low-dos

62 Primary lung cancers with microsatellite alterations at

63 lays), of which four received a diagnosis of primary lung cancer within the subsequent 2 years.